Top news of the week: 16.11.2022.
Press Release: Dupixent® (dupilumab) recommended for EU approval by the CHMP for the treatment of prurigo nodularis
Dupixent® (dupilumab) recommended for EU approval by the CHMP for the treatment of prurigo nodularis Recommendation is based on data from two pivotal trials showing Dupixent …
Beyond Biotech podcast 22: PacBio, Sierra Space
This week, we have two longer interviews, with guests from PacBio, Sierra Space, as well as our regular spot with JLL.
Characteristics Associated with a Positive PEST Screening Among Patients with Psoriasis Without a Diagnosis of Psoriatic Arthritis: Results from the Global Psoriasis and Beyond Study
Background/Purpose: Psoriatic arthritis (PsA) is a common clinical feature in patients (pts) with psoriasis (PsO); up to one third of PsO pts will develop PsA in their lifetime.1 Despite ...
Calliditas Spies Chinese Market As Tarpeyo Continues Upwards Sales Curve
The Swedish biotech’s successful launch in the US of Tarpeyo for immunoglobulin A nephropathy is progressing well and a Chinese approval is on the horizon as partner Everest’s application ...
Seagen Begins New Chapter with Novartis Vet David Epstein at the Helm
After six months of searching for its next chief executive, Washington’s largest biotech firm has found its match. On Thursday, Seagen named David R. Epstein as CEO.
Acrivon Becomes Biotech's 20th IPO of 2022 with $99M Offering
Acrivon Therapeutics announced the pricing of its initial public offering Tuesday, putting all of its 7,550,000 shares of common stock up for sale for $12.50 apiece.
A New Actinobacterial Chapter in the Genomic Encyclopedia of Bacteria and Archaea
Biosynthetic gene clusters for novel secondary metabolites were identified as part of the latest chapter in the Genomic Encyclopedia of Bacteria and Archaea.
BrainEver and 3P Biopharmaceuticals developing drug with hopes to cure ALS
3P and BrainEver are to collaborate on developing hEng1, a recombinant homeoprotein, to treat ALS or Parkinson’s disease.